Related Experiment Videos
Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters
Yasuto Akiyama1, Kouji Maruyama, Noriko Nara
1Growth Factor Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. yaakiyam@gan2.res.ncc.go.jp
Abstract:
Because the prognosis of patients with pancreatic cancer is very poor, development of a novel approach for treatment of this disease is vital. In the present study, we investigated the effect of dendritic cell (DC)-based immunotherapy against established syngeneic hamster pancreatic cancer named HPD1NR. Hamster enriched DCs were prepared from bone marrow (BM) by a culture for 7 days in the presence of mouse GM-CSF and mouse IL-4, and characterized by the expression of specific DC markers (DEC205, DC-SIGN) mRNA using in situ hybridization (ISH). DCs pulsed with tumor lysate and N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP) or DCs alone were injected s.c. weekly into HPD1NR-bearing hamsters three times. Tumor growth was significantly inhibited by 82% in hamsters treated with tumor lysate and DOTAP-pulsed DCs when compared with the PBS vehicle-treated group. These findings suggest that DC-based immunotherapy may be a useful approach for the treatment of pancreatic cancers.
Insights
Dendritic cell (DC)-based immunotherapy showed promise for pancreatic cancer treatment. This novel approach significantly inhibited tumor growth in preclinical models, suggesting a potential new therapy for patients.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Pancreatic cancer has a very poor prognosis, necessitating novel treatment strategies.
- Dendritic cell (DC)-based immunotherapy is an emerging field with potential therapeutic applications.
Purpose of the Study:
- To investigate the efficacy of DC-based immunotherapy against established pancreatic cancer in a syngeneic hamster model (HPD1NR).
Main Methods:
- Enriched hamster dendritic cells (DCs) were prepared from bone marrow.
- DCs were characterized for specific marker expression using in situ hybridization (ISH).
- DCs pulsed with tumor lysate and DOTAP, or DCs alone, were injected weekly into tumor-bearing hamsters.
Main Results:
- Treatment with tumor lysate and DOTAP-pulsed DCs significantly inhibited tumor growth by 82% compared to the control group.
- DCs alone showed some effect, but less pronounced than pulsed DCs.
Conclusions:
- DC-based immunotherapy, particularly with tumor lysate and DOTAP pulsing, demonstrates significant potential for treating pancreatic cancer.
- This approach warrants further investigation as a novel therapeutic strategy for pancreatic cancer.